Bringing science and development together through news and analysis

  • Clinton brokers deal on cut-price AIDS drugs


[DAR ES SALAAM] Some of the world's leading drug companies have agreed to halve the cost of antiretroviral drugs for HIV/AIDS patients in nine countries in the Caribbean, as well as Mozambique, Rwanda, South Africa and Tanzania.

The deal was struck last week by the William J. Clinton Foundation, led by the former US president, Bill Clinton.

Under the deal, the companies Cipla, Ranbaxy amd Aspen Pharmacare will cut the price of their antiretroviral drugs. Matrix Laboratories have also agreed to provide the active ingredient to these manufacturers at a reduced price.

For example, under the Clinton Foundation agreement, the price of one commonly used triple drug therapy combination will be reduced from US$300 to less than $140 per person per year.

"Today is a great day for the 2.2 million Tanzanians living with HIV, and those with full-blown AIDS," said President of Tanzania Benjamin William Mkapa in a speech welcoming the decision.

"For too long we in Africa who suffer most from the HIV/AIDS pandemic have argued and pleaded for much easier and affordable access to the drugs that can prevent HIV positive mothers from passing on the virus to their children [and the] drugs that can help HIV-positive breadwinners to live longer and be able to continue supporting their families."

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.